Governance
Accountability for a company preparing to operate in a regulated market.
NovaPharm separates statutory governance, proposed executive responsibilities and specialist advisory support so that public titles do not imply unverified appointments.
Statutory board
Four active directors are recorded at Companies House.
Executive responsibilities are described from the March 2026 business plan and remain subject to current board confirmation.
Vishal ChakravartyFounder & Chief Executive OfficerFounder and statutory directorPrabhakar Vitthal LahareManaging Director & Chief Operating OfficerStatutory director; executive title described in the March 2026 business planDr Girish Shantilal AchliyaDirector & Chief Scientific OfficerStatutory director; executive title described in the March 2026 business planDr Helly PanchalDirector, Technical & FormulationStatutory directorDr Nishita TrivediQuality & Regulatory AdviserSpecialist adviser described in the business plan; not a statutory director
Source: Companies House officer record, checked 11 July 2026. Companies House notes that filed information is not independently verified by the service.
Claims governance
A planned capability is not a current authorisation.
Public copy, product records and structured data use status language for regulatory preparation, partner development and technology roadmap items.
- No WDA(H) claim without official verification
- No PLPI licence or available-stock claim without product evidence
- No NHS supply or framework claim without confirmation
- No partner-logo or scope claim without permission
- No roadmap technology presented as deployed
Start a qualified conversation